CARLSBAD, Calif., and NEW YORK and SAN FRANCISCO, Jan. 27, 2016 /PRNewswire/ — A record number of life science industry executives attended the eighth annual Biotech Showcase™ investor and networking conference, held January 11–13 in San Francisco.
More than 2,500 executive-level delegates representing qualified private and public equity investors, industry analysts, bankers, pharmaceutical and biotechnology industry executives attended from 1,600 companies and participated in 5,650 one-to-one investor meetings.
Over 300 innovative company presentations took place featuring mid-small cap and private life sciences across the therapeutic spectrum as well as platform, diagnostic and tool companies hoping to pique the interest of the nearly 600 public, private and strategic investors in attendance.
“The widespread commercialization of the biotech industry presented life sciences investors and industry leaders with new opportunities and challenges this year as they gathered for this year’s Biotech Showcase. We are proud that the event has become a home base for the life sciences industry during the healthcare industry’s busiest week of the year,” said Sara Jane Demy, CEO of Demy-Colton Life Science Advisors.
“Although 2015 has been a volatile year for biotech, Biotech Showcase attendance is at an all time high. This speaks to the sustained interest within the investor community in biotech innovation,” said Anna Chrisman, Group Managing Director, EBD Group. “This year we provided more space, more one-on-one meetings which we hope resulted in more opportunities. It was overwhelmingly successful.”
Biotech Showcase is produced by Demy-Colton Life Science Advisors and EBD Group. Both organizations have a long history of producing high quality programs supporting the biotechnology and broader life sciences industry.